申请人:Yoshitomi Pharmaceutical Industries, Ltd.
公开号:US04960770A1
公开(公告)日:1990-10-02
A thienotriazolodiazepine compound of the formula: ##STR1## wherein Ar is phenyl, pyridyl, substituted phenyl or substituted pyridyl; R.sup.1 and R.sup.3 are the same or different and each is hydrogen, alkyl having 1 to 4 carbon atoms; R.sup.2 is hydrogen, alkyl having 1 to 4 carbon atoms or trifluoromethyl; R.sup.4 is straight or branched chain alkyl, alkenyl or alkynyl having 6 to 18 carbon atoms, or a thienodiazepine compound of the formula: ##STR2## wherein Ar, R.sup.1, R.sup.2 and R.sup.4 are as defined above, and pharmaceutically acceptable acid addition salt thereof. These compounds are useful as drugs for the treatment of circulatory diseases and various PAF-induced diseases. The compound (II) is also useful as an intermediate for preparing the compound (I).
一种噻唑二氮杂环己烷类化合物的化学式如下:##STR1## 其中Ar为苯基、吡啶基、取代苯基或取代吡啶基;R.sup.1和R.sup.3相同或不同,每个都是氢、具有1至4个碳原子的烷基;R.sup.2为氢、具有1至4个碳原子的烷基或三氟甲基;R.sup.4为直链或支链烷基、烯基或炔基,具有6至18个碳原子,或者为噻唑二氮杂环己烷类化合物的化学式如下:##STR2## 其中Ar、R.sup.1、R.sup.2和R.sup.4如上所定义,并且其药学上可接受的酸盐。这些化合物可用作治疗循环系统疾病和各种PAF诱导疾病的药物。化合物(II)还可用作制备化合物(I)的中间体。